热带病与寄生虫学

热带病与寄生虫学 ›› 2014, Vol. 12 ›› Issue (4): 190-193.doi: 10.3969/j.issn.1672-2302.2014.04.002

• 论著 • 上一篇    下一篇

莫西沙星联合治疗耐药肺结核的疗效观察

凌华毓，杨中   

  1. 246000  安徽安庆市，安庆市立医院呼吸内科（凌华毓），安庆市立医院核医学科（杨中）
  • 出版日期:2014-12-10 发布日期:2015-01-27

Therapeutic efficacy of combined moxifloxacin for drug-resistant pulmonary tuberculosis

Ling huayu1, yang zhong   

  1. Anqing Municipal Hospital, Anqing, 246000 China
  • Online:2014-12-10 Published:2015-01-27

被引次数

5

摘要：  目的  临床观察莫西沙星联合治疗耐药肺结核的疗效及其安全性。 方法  将62例耐药肺结核患者随机分为治疗组与对照组，两组患者除采用阿米卡星、对氨基水杨酸、丙硫异烟胺、环丝氨酸治疗外，治疗组加莫西沙星，对照组加左氧氟沙星，共观察21 个月（注射期6个月，非注射期15个月）。住院期间及出院均面视下督导治疗。 结果  注射期结束时，治疗组与对照组的痰涂片和痰培养结核杆菌阴转率分别为78.1%和46.7%；非注射期21个月时分别为93.7%和83.3%。X线影像学检查病灶吸收显效率分别是58%和53%；有效率分别90.1%和80.0%。 结论  莫西沙星联合抗结核药阿米卡星、氨基水杨酸、丙硫异烟胺、环丝氨酸等治疗耐药肺结核，具有促进痰菌阴转，病灶吸收等方面疗效，安全性良好。

关键词: 肺结核, 莫西沙星, 阿米卡星, 对氨基水杨酸, 丙硫异烟胺, 环丝氨酸, 耐药

Abstract:

 Objective  To observe the efficacies and safety of combined use of moxifloxacin in drug-resistant pulmonary tuberculosis. Methods  Sixty-two patients with drug-resistant pulmonary tuberculosis were randomly divided into treatment group and control group. The treatment group received additional moxifloxacin and the control group were given extra levofloxacin on the conventional amikacin, p-aminosalicylic acid, protionamide and cycloserine basis. The treatment duration lasted for 21 months, including injection for 6 months and oral use of the drug in 21 months. The entire treatment was carried out under surveillance of the providers during the hospital stay or follow up care. Results  By the end of injection treatment, negative conversion rate by sputum smear examination and sputum culturing was 78.1% for the treatment group and 46.7% for the controls, compared to 93.7% and 83.3% during the period of oral administration. X-ray imaging revealed that lesion absorption was excellent for 58% of the treatment group and 53% for the controls, and effective absorption rate were 90.1% and 80.0%, respectively. Conclusion  Combined moxifloxacin with amikacin, p-aminosalicylic acid, protionamide and  cycloserine can be effective and safe for drug-resistant pulmonary tuberculosis, with better negative conversion rate and lesion absorption.
【Key words】【Abstract】 Objective  To observe the efficacies and safety of combined use of moxifloxacin in drug-resistant pulmonary tuberculosis. Methods  Sixty-two patients with drug-resistant pulmonary tuberculosis were randomly divided into treatment group and control group. The treatment group received additional moxifloxacin and the control group were given extra levofloxacin on the conventional amikacin, p-aminosalicylic acid, protionamide and cycloserine basis. The treatment duration lasted for 21 months, including injection for 6 months and oral use of the drug in 21 months. The entire treatment was carried out under surveillance of the providers during the hospital stay or follow up care. Results  By the end of injection treatment, negative conversion rate by sputum smear examination and sputum culturing was 78.1% for the treatment group and 46.7% for the controls, compared to 93.7% and 83.3% during the period of oral administration. X-ray imaging revealed that lesion absorption was excellent for 58% of the treatment group and 53% for the controls, and effective absorption rate were 90.1% and 80.0%, respectively. Conclusion  Combined moxifloxacin with amikacin, p-aminosalicylic acid, protionamide and  cycloserine can be effective and safe for drug-resistant pulmonary tuberculosis, with better negative conversion rate and lesion absorption.

Key words: Pulmonary tuberculosis, Moxifloxacin, Amikacin, p-aminosalicylic acid, Protionamide, Cycloserine, Drug resistance